Product Pipeline
| Candidate & Indication | Development Stage | Status | ||||
|---|---|---|---|---|---|---|
| R & D | Preclinical | Phase 1 | Phase 2 | Phase 3 | ||
| Actimab-A (CD33) and CLAG-M Relapsed/Refractory AML |
R & D Phase complete
|
Preclinical Phase complete
|
Phase 1 Phase complete
|
Phase 2 Phase complete
|
Phase 3 Phase in progress
|
Phase 2/3 Trial Planned - Seeking Collaborator |
| Iomab-ACT (CD45) (apamistamab-I-131) Commercial CAR-T and Sickle Cell Disease conditioning |
R & D Phase complete
|
Preclinical Phase complete
|
Phase 1 Phase complete
|
Phase 2 Phase in progress
|
Phase 3 Phase not started
|
|
| Actimab-A (CD33) and Venetoclax Relapsed/Refractory AML |
R & D Phase complete
|
Preclinical Phase complete
|
Phase 1 Phase in progress
|
Phase 2 Phase not started
|
Phase 3 Phase not started
|
|
| Actimab-A Combinations PlannedMyeloid Malignancies |
R & D Phase complete
|
Preclinical Phase complete
|
Phase 1 Phase in progress
|
Phase 2 Phase not started
|
Phase 3 Phase not started
|
|
|
Iomab-B (CD45) (apamistamab-I-131)
Positive Results: Primary Endpoint Met (p<0.0001) BMT conditioning1 |
R & D Phase complete
|
Preclinical Phase complete
|
Phase 1 Phase complete
|
Phase 2 Phase complete
|
Phase 3 Phase in progress
|
Seeking U.S. Strategic Partner |
| R&D Programs Hematology and solid tumor indications |
R & D Phase complete
|
Preclinical Phase in progress
|
Phase 1 Phase not started
|
Phase 2 Phase not started
|
Phase 3 Phase not started
|
|
- BMT or HSCT (Hematopoietic Stem Cell Transplantation) is a procedure in which cells capable of reconstituting normal bone marrow function are transplanted to a patient.